Ironwood Pharmaceuticals IRWD Line of Credit Outstanding
Line of Credit Outstanding at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermLineOfCredit.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's line of credit outstanding.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's line of credit outstanding?
- Ironwood Pharmaceuticals (IRWD) reported line of credit outstanding of $385M in Q1 2026.
- How has Ironwood Pharmaceuticals's line of credit outstanding changed year-over-year?
- Ironwood Pharmaceuticals's line of credit outstanding decreased by 0.0% year-over-year, from $385M to $385M.
- What is the long-term trend for Ironwood Pharmaceuticals's line of credit outstanding?
- Over 2 years (2023 to 2025), Ironwood Pharmaceuticals's line of credit outstanding has grown at a 13.3% compound annual growth rate (CAGR), from $300M to $385M.
- What does line of credit outstanding mean?
- This reflects the amount drawn down from a revolving credit facility to support short-term working capital needs or operational liquidity. It provides insight into the company's reliance on external financing to bridge cash flow gaps during the normal course of business. High utilization of this facility may indicate tighter liquidity conditions or a need for additional capital.